MSMichele Schiariti

Michele Schiariti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michele Schiariti has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • HeartMan DSS: A decision support system for self-management of congestive heart failure

    by Marko Bohanec, Gennaro Tartarisco, Flavia Marino, Giovanni Pioggia, Paolo Emilio Puddu, Michele Salvatore Schiariti, Anneleen Baert, Sofie Pardaens, Els Clays, Aljoša Vodopija, et al.


  • Open Access

    Proof-of-concept trial results of the HeartMan mobile personal health system for self-management in congestive heart failure

    by Els Clays, Paolo Emilio Puddu, Mitja Luštrek, Giovanni Pioggia, Jan Derboven, Marilena Vrana, Johan De Sutter, Rita Le Donne, Anneleen Baert, Marko Bohanec, et al.

    This study tested the effectiveness of HeartMan—a mobile personal health system offering decisional support for management of congestive heart failure (CHF)—on health-related quality of life (HRQoL), self-management, exercise capacity, illness perception, mental and sexual health. A randomized controlled proof-of-concept trial (1:2 ratio of control:intervention) was set up with ambulatory CHF patients in stable condition in Belgium and Italy. Data were collected by means of a 6-min walking test and a number of standardized questionnaire instruments. A total of 56 (34 intervention and 22 control group) participants completed the study (77% male; mean age 63 years, sd 10.5). All depression and anxiety dimensions decreased in the intervention group (p < 0.001), while the need for sexual counselling decreased in the control group (p < 0.05). Although the group differences were not significant, self-care increased (p < 0.05), and sexual problems decreased (p < 0.05) in the intervention group only. No significant intervention effects were observed for HRQoL, self-care confidence, illness perception and exercise capacity. Overall, results of this proof-of-concept trial suggest that the HeartMan personal health system significantly improved mental and sexual health and self-care behaviour in CHF patients. These observations were in contrast to the lack of intervention effects on HRQoL, illness perception and exercise capacity.


  • Open Access

    A Personal Health System for Self-Management of Congestive Heart Failure (HeartMan): Development, Technical Evaluation, and Proof-of-Concept Randomized Controlled Trial

    by Mitja Luštrek, Marko Bohanec, Carlos Cavero Barca, Maria Costanza Ciancarelli, Els Clays, Amos Adeyemo Dawodu, Jan Derboven, Delphine De Smedt, Erik Dovgan, Jure Lampe, et al.

    Background: Congestive heart failure (CHF) is a disease that requires complex management involving multiple medications, exercise, and lifestyle changes. It mainly affects older patients with depression and anxiety, who commonly find management difficult. Existing mobile apps supporting the self-management of CHF have limited features and are inadequately validated.Objective: The HeartMan project aims to develop a personal health system that would comprehensively address CHF self-management by using sensing devices and artificial intelligence methods. This paper presents the design of the system and reports on the accuracy of its patient-monitoring methods, overall effectiveness, and patient perceptions.Methods: A mobile app was developed as the core of the HeartMan system, and the app was connected to a custom wristband and cloud services. The system features machine learning methods for patient monitoring: continuous blood pressure (BP) estimation, physical activity monitoring, and psychological profile recognition. These methods feed a decision support system that provides recommendations on physical health and psychological support. The system was designed using a human-centered methodology involving the patients throughout development. It was evaluated in a proof-of-concept trial with 56 patients.Results: Fairly high accuracy of the patient-monitoring methods was observed. The mean absolute error of BP estimation was 9.0 mm Hg for systolic BP and 7.0 mm Hg for diastolic BP. The accuracy of psychological profile detection was 88.6%. The F-measure for physical activity recognition was 71%. The proof-of-concept clinical trial in 56 patients showed that the HeartMan system significantly improved self-care behavior (P=.02), whereas depression and anxiety rates were significantly reduced (P<.001), as were perceived sexual problems (P=.01). According to the Unified Theory of Acceptance and Use of Technology questionnaire, a positive attitude toward HeartMan was seen among end users, resulting in increased awareness, self-monitoring, and empowerment.Conclusions: The HeartMan project combined a range of advanced technologies with human-centered design to develop a complex system that was shown to help patients with CHF. More psychological than physical benefits were observed.Trial Registration: ClinicalTrials.gov NCT03497871; https://clinicaltrials.gov/ct2/history/NCT03497871.International Registered Report Identifier (IRRID): RR2-10.1186/s12872-018-0921-2


  • Open Access

    Association of patient-reported outcomes and heart rate trends in heart failure: a report from the Chiron project

    by Luca Monzo, Michele Schiariti, Pietro Fedele Calvisi, Silvio Bonfiglio, Mitja Luštrek, Paolo E. Puddu

    Patient-reported outcomes (PROs) have been previously considered “soft” end-points because of the lack of association of the reported outcome to measurable biological parameters. The present study aimed to assess whether electrocardiographic measures are associated to PROs changes. We evaluated the association between heart rate (HR), QRS and QT/QTc durations and PROs, classified as “good” or “bad” according to the patients’ overall feeling of health, in patients from the Chiron project. Twenty-four chronic heart failure (HF) patients were enrolled in the study (71% male, mean age 62.9 ± 9.4 years, 42% ischemic etiology, 15 NYHA class II and 9 class III) providing 1086 days of usable physiological recordings (4 hours/day). The mean HR was significantly higher in the “bad” than in the “good” PROs class (74.0 ± 6.4 bpm vs 68.0 ± 7.2 bpm; p < 0.001). Conversely, the ratio between movement and rest activities showed significantly higher values in “good” compared to “bad” PROs. We also found significantly longer QTc and QRS durations in patients with “bad” PROs compared to patients with “good” PROs. That in patients with mild to moderate HF, higher HR, wider QRS and longer QTc, as well as a reduced HR ratio between movement and rest, were associated with “bad” PROs is clinically noteworthy because the association of worse PROs with measurable variations of biological parameters may help physicians in evaluating PROs reliability itself and in their clinical decisions. Whether a timely intervention on these biological parameters may prevent adverse outcomes is important and deserves to be investigated in further studies.


  • Open Access

    Homeostatic Left Heart integration and disintegration links atrio-ventricular covariation’s dyshomeostasis in Hypertrophic Cardiomyopathy

    by Paolo Piras, Concetta Torromeo, Antonietta Evangelista, Stefano Gabriele, Giuseppe Esposito, Paola Nardinocchi, Luciano Teresi, Andrea Madeo, Michele Schiariti, Valerio Varano, et al.

    Left ventricle and left atrium are and have been practically always analyzed separately in common clinically and non-clinically oriented cardiovascular investigations. Both classic and speckle tracking echocardiographic data contributed to the knowledge about deformational impairments occurring in systo-diastolic differences. Recently new trajectory based approaches allowed a greater awareness about the entire left ventricle or left atrium revolution and on their deficiencies that take place in presence of hypertrophic cardiomyopathy. However, surprisingly, the concomitant function of the two left heart chambers has not been analyzed for their geometrical/mechanical relationship. For the first time we study here, by acquiring left ventricle and left atrial geometries on the same heartbeat, the trajectory attributes of the entire left heart treated as a whole shape and the shape covariation of its two subunits. We contrasted healthy subjects with patients affected by hypertrophic cardiomyopathy. We found impaired left heart trajectory mainly in terms of orientation and size. More importantly, we found profound differences in the direction of morphological covariation of left ventricle and left atrium. These findings open to new perspectives in pathophysiological evaluation of different diseases by allowing the appreciation of concomitant functioning of both left heart whole geometry and of its two chambers.


  • Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone

    by Mitja Lainscak, Francesco Pelliccia, Giuseppe Rosano, Cristiana Vitale, Michele Schiariti, Cesare Greco, Giuseppe Speziale, Carlo Gaudio


  • Aldosterone and testosterone: two steroid hormones structurally related but with opposite electrophysiological properties during myocardial ischemia–reperfusion

    by Joachim Alexandre, Paul Milliez, René Rouet, Alain Manrique, Stéphane Allouche, Gianfranco Piccirillo, Michele Schiariti, Paolo‐Emilio Puddu

    Steroid hormones appear to be a key factor in the gender differences in the rates and severity of cardiovascular diseases. Aldosterone and testosterone have typical steroid ring structure, but despite this, they demonstrate very different properties. During acute myocardial ischemia–reperfusion, the deleterious impact of aldosterone is now well established. Conversely, the electrophysiological impact of testosterone in this context remained unknown. We used female rabbit in vitro models and standard microelectrode technique including right ventricle mimicking the ‘border zone’ existing between normal and ischemic/reperfused areas and isolated right ventricle experiments to assess the acute electrophysiological impact of both aldosterone and testosterone. During ischemia–reperfusion, acute superfusion of 10 and 100 nmol/L testosterone decreased normoxic and reperfused action potential duration at 90% (APD90), systematically induced conduction blocks, and decreasedAPD90dispersion between ischemic and nonischemic areas (from 98 ± 4 to 57 ± 7 ms and 66 ± 3 ms, for, respectively, testosterone 10 and 100 nmol/L,P < 0.05). Testosterone 10 and 100 nmol/L concomitantly decreased sustained premature ventricular contraction (PVC) occurrence (from 55 to 0%,P < 0.05). Conversely, aldosterone 10 and 100 nmol/L increased normoxic and reperfusedAPD90,APD90dispersion, and reperfusion‐inducedPVCs. Furthermore, testosterone demonstrated cycle length‐dependent effects onAPD90for high heart rate, whereas aldosterone did not exhibit any significant effect compared with controls. During acute myocardial ischemia–reperfusion, acute superfusion of physiological concentrations of testosterone seemed to be anti‐arrhythmic by removing a pro‐arrhythmic substrate (APD90dispersion), inducing conduction blocks and decreasing triggered activities (PVCoccurrence). Further experiments are warranted to confirm our results.


  • Open Access

    Personalized Reduced 3-Lead System formation methodology for Remote Health Monitoring Applications and Reconstruction of Standard 12-Lead system

    by Sidharth Maheshwari, Amit Acharyya, Michele Schiariti, Paolo Emilio Puddu

    Personalized Reduced 3-Lead System formation methodology for Remote Health Monitoring Applications and Reconstruction of Standard 12-Lead system